A chimeric IL-6/IL-1β fusokine was engineered to test the hypothesis that enforced co-engagement of IL-6 and IL-1β signaling pathways would confer a gain-of-function phenotype in T cells and promote robust anti-tumor immunity. Here, IL1B is linked to neoplasm.